NO20062104L - Kombinasjonsterapi for HCV-infeksjon - Google Patents

Kombinasjonsterapi for HCV-infeksjon

Info

Publication number
NO20062104L
NO20062104L NO20062104A NO20062104A NO20062104L NO 20062104 L NO20062104 L NO 20062104L NO 20062104 A NO20062104 A NO 20062104A NO 20062104 A NO20062104 A NO 20062104A NO 20062104 L NO20062104 L NO 20062104L
Authority
NO
Norway
Prior art keywords
present
hcv infection
combination therapy
relates
combinations
Prior art date
Application number
NO20062104A
Other languages
English (en)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20062104L publication Critical patent/NO20062104L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse vedrører terapeutiske kombinasjoner omfattende VX-497, ribavirin og interferon. Foreliggende oppfinnelse vedrører også fremgangsmåter som anvender de terapeutiske kombinasjonene ifølge foreliggende oppfirmelse for å behandle HCV-infeksjon eUer for å lindre ett eller flere symptomer derav i en pasient. Foreliggende oppfinnelse tilveiebringer også kit omfattende kombinasjonene ifølge foreliggende oppfirmelse.
NO20062104A 2003-10-11 2006-05-10 Kombinasjonsterapi for HCV-infeksjon NO20062104L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
PCT/US2004/033739 WO2005037274A1 (en) 2003-10-11 2004-10-12 Combination therapy for hcv infection

Publications (1)

Publication Number Publication Date
NO20062104L true NO20062104L (no) 2006-05-10

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062104A NO20062104L (no) 2003-10-11 2006-05-10 Kombinasjonsterapi for HCV-infeksjon

Country Status (17)

Country Link
US (1) US20050112093A1 (no)
EP (1) EP1670462A1 (no)
JP (1) JP2007508326A (no)
KR (1) KR20060120037A (no)
CN (1) CN1882335A (no)
AR (1) AR045870A1 (no)
AU (1) AU2004281747A1 (no)
BR (1) BRPI0415249A (no)
CA (1) CA2541857A1 (no)
IL (1) IL174864A0 (no)
MX (1) MXPA06004077A (no)
NO (1) NO20062104L (no)
PE (1) PE20050477A1 (no)
RU (1) RU2006115916A (no)
TW (1) TW200528104A (no)
WO (1) WO2005037274A1 (no)
ZA (1) ZA200602912B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129407A0 (en) 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2646229A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
CN102470162A (zh) * 2009-06-30 2012-05-23 明治制果药业株式会社 用于治疗难治性c型慢性肝炎的药剂以及方法
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286662B6 (sk) * 1996-04-23 2009-03-05 Vertex Pharmaceuticals Incorporated Deriváty močoviny, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie ako inhibítorov aktivity IMPDH enzýmu
CZ300540B6 (cs) * 1998-05-15 2009-06-10 Schering Corporation Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
WO2003101199A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors

Also Published As

Publication number Publication date
US20050112093A1 (en) 2005-05-26
AR045870A1 (es) 2005-11-16
EP1670462A1 (en) 2006-06-21
JP2007508326A (ja) 2007-04-05
PE20050477A1 (es) 2005-08-24
ZA200602912B (en) 2007-06-27
WO2005037274A1 (en) 2005-04-28
CN1882335A (zh) 2006-12-20
MXPA06004077A (es) 2006-06-27
RU2006115916A (ru) 2007-12-10
TW200528104A (en) 2005-09-01
KR20060120037A (ko) 2006-11-24
BRPI0415249A (pt) 2006-12-12
IL174864A0 (en) 2008-04-13
CA2541857A1 (en) 2005-04-28
AU2004281747A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
NO20062104L (no) Kombinasjonsterapi for HCV-infeksjon
UA103496C2 (uk) Комбінація інгібітора протеази ns3 hcv з інтерфероном і рибавірином
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
WO2004099246A3 (en) Peptides for use in treating obesity
WO2006130627A3 (en) Methods for treating hepatitis c
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
PL374865A1 (en) Treatment of tnf alpha related disorders
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
BRPI0511367B8 (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
CY1108808T1 (el) Ενωσεις μοτιλιδης
MX2009011930A (es) Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
DE602006012115D1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
DK1476468T3 (da) Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
ATE451934T1 (de) Pharmazeutische zusammensetzung zur behandlung von rhinitiden
SE0302304D0 (sv) Novel compounds
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
GB0209998D0 (en) Use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application